| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $166,661,521 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 003 | 4 | NIH | 8/4/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 003 | 4 | NIH | 8/4/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 002 | 4 | NIH | 7/30/2026 | $50,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 002 | 4 | NIH | 7/30/2026 | $66,666 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 002 | 4 | NIH | 7/30/2026 | $150,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | T32GM159581 | Training Program in Cellular and Molecular Membrane Biology | 000 | 2 | NIH | 5/28/2026 | $421,217 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 002 | 4 | NIH | 7/30/2026 | $378,595 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 004 | 4 | NIH | 8/13/2026 | $119,213 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21CA302901 | Protein Degradation Strategies to Overcome Menin Drug Resistance in Acute Leukemias | 000 | 1 | NIH | 5/15/2026 | $399,829 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R00NS134734 | Dynamics of Hippocampal Inputs in Alzheimer's Disease | 000 | 3 | NIH | 3/6/2026 | $248,936 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R03DE035988 | Citrate regulation in amelogenesis | 000 | 1 | NIH | 6/11/2026 | $311,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R37NS141786 | SGLT2 - Novel Molecular Mechanism of AQP4 Regulation | 000 | 1 | NIH | 3/5/2026 | $602,065 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | S10OD040102 | High-Throughput Automated Patch Clamp Instrument | 000 | 1 | NIH | 5/1/2026 | $750,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | RF1AG059651 | PROMIS Profile Measures for Older Adults with Cognitive Impairment-Developing Versions for Older Adults with Cognitive Impairment and for Proxy Completion | 001 | 6 | NIH | 6/8/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | RF1AG059651 | PROMIS Profile Measures for Older Adults with Cognitive Impairment-Developing Versions for Older Adults with Cognitive Impairment and for Proxy Completion | 000 | 6 | NIH | 4/29/2026 | $3,284,905 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | DP2AI192747 | Gut Microbial Protein Metabolism in Food Allergy and Oral Immunotherapy Efficacy | 000 | 1 | NIH | 1/28/2026 | $466,500 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI190371 | Multi-omics Analysis of Bacteria-Host Interactions in Brugia malayi, a Medically Important Nematode with a Wolbachia Endosymbiont | 000 | 1 | NIH | 3/27/2026 | $678,218 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01EY038421 | Development, Refinement, and Validation of Sensitive and Robust AO-OCT Glaucoma Biomarkers | 000 | 1 | NIH | 4/29/2026 | $571,206 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AI196697 | A cord-blood specific subset of human gamma-delta T cells with distinct functional features | 000 | 1 | NIH | 2/3/2026 | $455,500 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI200893 | Lymph node structure and function in tolerance: Role of Fibroblastic Reticular Cells | 000 | 1 | NIH | 7/13/2026 | $564,436 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25TW011804 | Strengthening Capacity in Health Research Ethics and Methodology in The Gambia | 002 | 5 | NIH | 7/3/2026 | $69,324 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25TW011804 | Strengthening Capacity in Health Research Ethics and Methodology in The Gambia | 001 | 5 | NIH | 7/3/2026 | $3,564 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25TW011804 | Strengthening Capacity in Health Research Ethics and Methodology in The Gambia | 000 | 5 | NIH | 6/24/2026 | $167,662 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL181475 | Cell type-specific roles of integrin CD11b in atherosclerosis regression | 000 | 2 | NIH | 6/26/2026 | $737,655 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL180768 | Functional characterization of genes and genetic variants associated with hypoplastic heart syndrome in Drosophila | 000 | 2 | NIH | 6/24/2026 | $761,476 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DE032225 | The Role of Testosterone on Mediating Sex and Gender Influences on Chronic Orofacial Pain Conditions | 000 | 4 | NIH | 8/10/2026 | $255,985 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS145443 | Mechanisms and intervention of cGAS signaling in brain trauma-induced neuroinflammation and neurodegeneration | 000 | 2 | NIH | 8/5/2026 | $640,343 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA061796 | Mechanistic Evaluation of Gabapentin and Opioid Polypharmacy | 001 | 1 | NIH | 6/3/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA061796 | Mechanistic Evaluation of Gabapentin and Opioid Polypharmacy | 000 | 1 | NIH | 5/28/2026 | $659,796 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K01AI187720 | Defining the gastrointestinal immune and microbiome response to shigella infection in children | 000 | 1 | NIH | 5/28/2026 | $159,764 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01EB036730 | Fast motion navigators for brain diffusion MRI | 000 | 1 | NIH | 5/27/2026 | $516,628 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NR021713 | Empowering Baltimore youth through applied research experiences to improve diet quality in older adults living in healthy food priority areas | 000 | 1 | NIH | 5/21/2026 | $2,160,854 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K99AR085178 | Investigating the impact of abnormal lipid metabolism on mouse intervertebral disc | 000 | 2 | NIH | 8/20/2026 | $115,301 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K99CA312671 | Transcriptomic, Genomic, and Microenvironmental Heterogeneity in pancreatic precancer: subtyping, classification, and cross-comparison | 000 | 1 | NIH | 5/7/2026 | $123,823 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25AG088402 | Entrepreneurship & Science Communication for Aging and Aging-related Research (ESCAAR) Program for Doctoral Students and Postdoctoral Scholars | 000 | 2 | NIH | 6/5/2026 | $262,873 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R00CA279786 | Translation Rewiring Underlines Drug Resistance to Lethal Targeted Ribosome Biogenesis Therapeutics in Cancer | 000 | 3 | NIH | 7/2/2026 | $248,999 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI192916 | Shark nanobodies identify pan-coronavirus spike sites of vulnerability fortherapeutic intervention | 000 | 1 | NIH | 5/6/2026 | $896,045 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | F32AI200207 | Menstrual phase targeted therapy: a novel strategy to improve clearance and reduce recurrence of bacterial vaginosis | 001 | 1 | NIH | 5/7/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | F32AI200207 | Menstrual phase targeted therapy: a novel strategy to improve clearance and reduce recurrence of bacterial vaginosis | 000 | 1 | NIH | 5/7/2026 | $79,764 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01MH139606 | Quantifying cerebellar multi-omic and synaptic features of autism spectrum disorders | 000 | 1 | NIH | 3/9/2026 | $762,566 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA065079 | Impact of opioid use disorder on mitochondrial dysfunction among antiretroviral therapy-receiving aging people with HIV. | 001 | 1 | NIH | 6/25/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K01AI196239 | Host-pathogen-microbiome interactions in Mycoplasma genitalium infection, pathology, and treatment: experiments in a 3D organotypic cervical epithelium model to strengthen clinical guidelines | 000 | 1 | NIH | 4/24/2026 | $155,893 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AI187784 | Plant-derived nanoparticles as a sepsis therapy | 000 | 1 | NIH | 6/26/2026 | $233,250 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA065079 | Impact of opioid use disorder on mitochondrial dysfunction among antiretroviral therapy-receiving aging people with HIV. | 000 | 1 | NIH | 3/10/2026 | $685,937 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AT013426 | Green Light Therapy and Brain Mechanisms of Pain and Anxiety | 000 | 2 | NIH | 6/18/2026 | $200,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AT013426 | Green Light Therapy and Brain Mechanisms of Pain and Anxiety | 000 | 2 | NIH | 6/18/2026 | $540,090 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AG092405 | HCN Channels Mediate Olfactory Dysfunction in Aging and Neurological Disease | 000 | 1 | NIH | 2/18/2026 | $649,766 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | F31AA032134 | Targeting prefrontostriatal circuits to rescue alcohol-induced behavioral inflexibility | 001 | 1 | NIH | 4/17/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | F31AA032134 | Targeting prefrontostriatal circuits to rescue alcohol-induced behavioral inflexibility | 000 | 1 | NIH | 4/17/2026 | $40,624 |
|
